Generic Name and Formulations:
Chlordiazepoxide HCl 5mg, clidinium bromide 2.5mg; caps.
Valeant Pharmaceuticals, Inc
Indications for LIBRAX:
Adjunct in peptic ulcer. Irritable bowel syndrome. Acute enterocolitis.
Individualize. Usually 1–2 caps 3–4 times daily before meals and at bedtime. Elderly or debilitated: max 2 caps daily initially, then may increase gradually.
Glaucoma. GI or GU obstruction.
Risks from concomitant use with opioids; see Interactions. Monitor for paradoxical reactions. Depression. Suicidal tendencies (monitor). Hepatic and renal impairment. Obtain LFTs and blood counts periodically in prolonged use. Drug or alcohol abuse. Write ℞ for smallest practical amount. Avoid abrupt cessation. Elderly. Debilitated. Pregnancy; avoid during the first trimester. Nursing mothers: not recommended.
Benzodiazepine + anticholinergic.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants. Concomitant other psychotropic agents (eg, MAOIs, phenothiazines): not recommended. Increased constipation with concomitant other spasmolytic agents and/or a low residue diet. May rarely interfere with oral anticoagulants.
Drowsiness, anticholinergic effects (eg, dry mouth, blurred vision, urinary hesitancy, constipation), ataxia, confusion; rare: jaundice, blood dyscrasias.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally